Index test	MRI populationa	Target condition	Prevalence	NPV (95% CI)b	PPV (95% CI)b
MRI	Positive + Negative	G = 1	0.10	0.89 (0.87 to 0.91)	0.10 (0.09 to 0.11)
			0.20	0.79 (0.74 to 0.82)	0.20 (0.18 to 0.21)
			0.30	0.68 (0.63 to 0.73)	0.29 (0.27 to 0.31)
			0.40	0.58 (0.52 to 0.64)	0.39 (0.37 to 0.42)
			0.50	0.48 (0.42 to 0.54)	0.49 (0.47 to 0.52)
		G ≥ 2	0.10	0.97 (0.96 to 0.98)	0.14 (0.13 to 0.15)
			0.20	0.94 (0.91 to 0.96)	0.27 (0.25 to 0.28)
			0.30	0.91 (0.86 to 0.94)	0.38 (0.36 to 0.40)
			0.40	0.86 (0.79 to 0.91)	0.49 (0.47 to 0.51)
			0.50	0.81 (0.72 to 0.87)	0.59 (0.57 to 0.61)
		G ≥ 3	0.05	0.99 (0.98 to 1.00)	0.07 (0.06 to 0.08)
			0.10	0.99 (0.97 to 0.99)	0.14 (0.13 to 0.16)
			0.15	0.98 (0.95 to 0.99)	0.21 (0.19 to 0.23)
			0.20	0.97 (0.93 to 0.99)	0.27 (0.25 to 0.29)
			0.25	0.96 (0.90 to 0.98)	0.33 (0.30 to 0.36)
MRI‐TBx	Positive	G = 1	0.10	0.95 (0.90 to 0.97)	0.94 (0.11 to 1.00)
			0.20	0.89 (0.80 to 0.94)	0.97 (0.21 to 1.00)
			0.30	0.83 (0.70 to 0.91)	0.98 (0.32 to 1.00)
			0.40	0.75 (0.60 to 0.86)	0.99 (0.42 to 1.00)
			0.50	0.67 (0.50 to 0.81)	0.99 (0.52 to 1.00)
		G ≥ 2	0.10	0.98 (0.96 to 0.98)	0.60 (0.47 to 0.72)
			0.20	0.95 (0.92 to 0.97)	0.77 (0.67 to 0.86)
			0.30	0.92 (0.88 to 0.94)	0.85 (0.77 to 0.91)
			0.40	0.88 (0.82 to 0.91)	0.90 (0.84 to 0.94)
			0.50	0.83 (0.75 to 0.88)	0.93 (0.89 to 0.96)
		G ≥ 3	0.05	ID	ID
			0.10	ID	ID
			0.15	ID	ID
			0.20	ID	ID
			0.25	ID	ID
MRI pathway	Positive + Negative	G = 1	0.10	0.93 (0.91 to 0.95)	0.89 (0.21 to 1.00)
			0.20	0.86 (0.82 to 0.89)	0.95 (0.37 to 1.00)
			0.30	0.78 (0.73 to 0.82)	0.97 (0.50 to 1.00)
			0.40	0.69 (0.63 to 0.75)	0.98 (0.61 to 1.00)
			0.50	0.60 (0.53 to 0.66)	0.99 (0.70 to 1.00)
		G ≥ 2	0.10	0.97 (0.96 to 0.98)	0.69 (0.56 to 0.79)
			0.20	0.93 (0.90 to 0.95)	0.83 (0.74 to 0.90)
			0.30	0.89 (0.85 to 0.92)	0.90 (0.83 to 0.94)
			0.40	0.84 (0.78 to 0.89)	0.93 (0.88 to 0.96)
			0.50	0.78 (0.70 to 0.84)	0.95 (0.92 to 0.97)
		G ≥ 3	0.05	ID	ID
			0.10	ID	ID
			0.15	ID	ID
			0.20	ID	ID
			0.25	ID	ID
SBx	NA	G = 1	0.10	0.95 (0.91 to 0.98)	0.87 (0.20 to 0.99)
			0.20	0.90 (0.81 to 0.95)	0.94 (0.37 to 1.00)
			0.30	0.84 (0.71 to 0.92)	0.96 (0.50 to 1.00)
			0.40	0.77 (0.61 to 0.88)	0.98 (0.61 to 1.00)
			0.50	0.69 (0.52 to 0.83)	0.98 (0.70 to 1.00)
		G ≥ 2	0.10	0.96 (0.88 to 0.99)	1.00 (0.41 to 1.00)
			0.20	0.92 (0.76 to 0.97)	1.00 (0.61 to 1.00)
			0.30	0.86 (0.65 to 0.95)	1.00 (0.73 to 1.00)
			0.40	0.80 (0.54 to 0.93)	1.00 (0.81 to 1.00)
			0.50	0.73 (0.44 to 0.90)	1.00 (0.86 to 1.00)
		G ≥ 3	0.05	ID	ID
			0.10	ID	ID
			0.15	ID	ID
			0.20	ID	ID
			0.25	ID	ID
aData did not allow differentiation between the mix of included participants (biopsy‐naïve and prior‐negative biopsy men). bNPV and PPV are based on the Bayes’ theorem, using the point estimates and 95% confidence intervals of the pooled positive and negative likelihood ratio and prespecified prevalences. CI: confidence interval; G: International Society of Urological Pathology grade; ID: inadequate data; MRI: magnetic resonance imaging; MRI pathway: magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; MRI‐TBx: magnetic resonance imaging‐targeted biopsy; NA: not applicable; NPV: negative predictive value; PPV: positive predictive value; SBx: systematic biopsy